Corporate Brochures for IBM
Ion Biotechnology México S.A. de C.V. is dedicated to bringing the benefits of Ion Biotechnology Aqueous Ligands (IBAL) to Latino markets. Our aim is to expand throughout Central and South American regions, ensuring widespread access to these innovative therapies. We take a strategic approach to developing a pipeline of finished drug candidates. By combining metal ions, tailoring indications, and implementing innovative administration methods, we deliver effective and targeted therapies. Collaboration with licensed partners is crucial for conducting comprehensive clinical trials. Through partnerships, we advance medical knowledge and gain valuable insights into the potential of IBAL-based therapies.To ensure widespread access, we plan to sublicense distribution rights to reputable entities within our territories. This strategic approach guarantees that our therapies reach patients in need, improving healthcare throughout Central and South America. Join us on our journey to transform healthcare in Latino markets. Together, we can make a lasting impact through the power of IBAL.
For more information, refer to the attached file.
Related Articles
Corporate Brochure for IAG
The Ionic Alliance Group “IAG” is leading the international research, development, and manufacturing of IBAL, a new form of biotechnology. The Ionic Alliance Community fosters a collaborative environment where information, ideas, and data relating to ...
Ion Biotechnology Mexico Corporate Brochure
Ion Biotechnology México S.A de C.V. is focused on introducing Ion Biotechnology Aqueous Ligands (IBAL) to Latino markets in Central and South America, with the goal of ensuring widespread access to innovative therapies. Our strategic approach ...
IBM Analysis of HAIs in Mexico
Our report explores the prevalence, causes, and potential prevention strategies for infections in healthcare settings in Mexico. For more information, refer to the attached file.
Ion Gel ZCM-25® Technical Data Sheet
Read detailed insights into the composition, physical properties, and safety profile of Ion Gel ZCM-25®. For more information, refer to the attached file.
Modification to the Conditions of the Sanitary Registration COFEPRIS for the Ion Gel ZCM-25®
At the beginning of 2023, a request was made to the Federal Commission for Prevention and Sanitary Risks (COFEPRIS) for a change of National Manufacturer. Finally, on March 22, 2024, Zeyco Laboratories S.A. de C.V. was approved as the manufacturer of ...